RAPT Therapeutics (RAPT)

• Market cap: $138M
• 1 day: -4.59%
• 5 days: -12.61%
• 1 month: 39.06%
• 3 months: -11.11%
• 6 months: 14.29%
• Year to date: -36.20%
• 1 year: -70.11%
• 5 years: -95.41%
• 10 years: -92.00%
• Sector: Healthcare
• Industry: Biotechnology

About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Employees: 67

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

20% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 6 (+1) [Q1 2025]

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

1% more funds holding

Funds holding: 91 [Q4 2024] → 92 (+1) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

20% less capital invested

Capital invested by funds: $199M [Q4 2024] → $160M (-$39.5M) [Q1 2025]

263.62% less ownership

Funds ownership: 362.96% [Q4 2024] → 99.34% (-263.62%) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 4% downside
• Avg. target: $3.50 237% upside
• High target: $6 477% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

UBS Eliana Merle	4% downside $1	Neutral Maintained	22 May 2025
HC Wainwright & Co. Emily Bodnar	477% upside $6	Buy Assumed	22 May 2025